ruxolitinib (Jakafi, Opzelura)
Jump to navigation
Jump to search
Indications
- 1st FDA-approved drug for treatment of myelofibrosis
- polycythemia vera
- atopic dermatitis (topical)[2]
- vitiligo (Opzelura, topical FDA-approved)*[3]
- glucocorticoid-refractory chronic graft-versus-host disease[4]
* after 2 years, 84% with > 50% improvement in facial vitiligo, 52% with 90% improvement[3]
Dosage
Tabs: 5, 10, 15, 20, 25 mg
Cream: 1.5%
Adverse effects
Mechanism of action
- inhibits JAK1 & JAK2
- reduces myelofibrosis-related symptoms, including splenomegaly, abdominal pain, night sweats, bone or muscle pain, itching
More general terms
References
- ↑ Chestecka Z Medscape Oncology, 11/16/2011 FDA Approves Ruxolitinib, First Drug Ever for Myelofibrosis http://www.medscape.com/viewarticle/753682
- ↑ 2.0 2.1 Kim BS, Howell MD, Sun K et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol 2020 Feb; 145:572. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31629805 Free Article https://www.jacionline.org/article/S0091-6749(19)31326-0/fulltext
- ↑ 3.0 3.1 3.2 Bankhead C Topical JAK Inhibitor Shows Promise in Vitiligo. Half of patients had 90% improvement after 2 years of treatment. MedPage Today April 30, 2021 https://www.medpagetoday.com/meetingcoverage/aad/92371
Forand RL FDA approves Opzelura cream for vitiligo. Healio. Dermatology. July 19, 2022 https://www.healio.com/news/dermatology/20220719/fda-approves-opzelura-cream-for-vitiligo
Harris JE, et al Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: 104-week data from a phase II study. American Academy of Dermatology (AAD) 2021; Poster 27535. https://www.medpagetoday.com/meetingcoverage/aad/92371
Pandya AG, et al Addition of narrow-band ultraviolet B phototherapy to ruxolitinib cream in patients with vitiligo. American Academy of Dermatology (AAD) 2021; Poster 27636. - ↑ 4.0 4.1 4.2 Zeiser R, Polverelli N, Ram R et al Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med 2021; 385:228-238. July 15. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34260836 https://www.nejm.org/doi/full/10.1056/NEJMoa2033122